著者
Eline H Ploumen Rosaly A Buiten Paolo Zocca Carine JM Doggen Adel Aminian Carl E Schotborgh Gillian AJ Jessurun Ariel Roguin Peter W Danse Edouard Benit Clemens von Birgelen
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
pp.CJ-21-0292, (Released:2021-07-13)
参考文献数
31

Background:At 1 year, the international randomized BIONYX trial (ClinicalTrials.gov:NCT02508714) established non-inferiority regarding safety and efficacy of the novel Resolute Onyx zotarolimus-eluting stent (RO-ZES) vs. the Orsiro sirolimus-eluting stent (O-SES). Although the RO-ZES is used in daily practice, no clinical results have been published beyond 2 years.Methods and Results:We assessed 3-year clinical outcomes of 2,488 all-comers after percutaneous coronary intervention (PCI) with RO-ZES vs. O-SES. The main endpoint was target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction (MI), or target vessel revascularization. Time-to-endpoints was assessed by Kaplan-Meier methods and between-group comparisons by log-rank tests. Follow-up was available in 2,433/2,488 (97.8%) patients. There was no significant between-stent difference in TVF (RO-ZES 112/1,243 [9.2%] vs. O-SES 109/1,245 [8.9%], hazard ratio [HR]: 1.03, 95% confidence interval [CI] 0.79–1.34; Plog-rank=0.85) and its individual components. The all-cause mortality was significantly lower after PCI with RO-ZES (3.7% vs.5.4%, HR: 0.67, 95% CI 0.46–0.97; Plog-rank=0.034), but cardiac mortality did not differ significantly (1.1% vs.1.9%, HR: 0.56, 95% CI 0.28–1.11; Plog-rank=0.09). Definite-or-probable stent thrombosis rates were low for both groups (0.6% vs.1.2%, HR: 0.46, 95% CI 0.19–1.14; Plog-rank=0.09).Conclusions:This first 3-year randomized assessment of the RO-ZES showed a favorable rate of TVF that matched the outcomes of patients treated with O-SES. We observed a lower rate of all-cause death in the RO-ZES group, but long-term clinical follow-up is of interest.

言及状況

外部データベース (DOI)

Twitter (2 users, 2 posts, 4 favorites)

HTSR colleagues published: “First report of 3-year clinical outcome after treatment with novel resolute onyx stents in the randomized BIONYX trial” in the Circulation Journal. Read the full-text here: https://t.co/29S3I0G8OQ
Resolute Onyx vs. Orsiro DES showed similar 3-yr safety and efficacy in the randomized BIONYX trial. All-cause mortality was lower with Resolute Onyx, yet cardiac death did not differ. By Ploumen et al. @Eline49076718 https://t.co/h1SXp3v1ws #circ_j https://t.co/l6FtErEyPE

収集済み URL リスト